To further evaluate the prognostic value of CD204+ST Mφs in different UCB patient subgroups, patients were stratified according to age (Fig. 4A–4B), tumor size (Fig. 4C–4D), tumor stage (Fig. 4E–4F), and histological grade (Fig. 4G–4H). This evidence concerns the gene MSR1 and neoplasm.